ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have been given an average rating of “Buy” by the nine analysts that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $80.13.

Several analysts have issued reports on ANIP shares. Jefferies Financial Group started coverage on ANI Pharmaceuticals in a research report on Friday, March 14th. They set a “buy” rating and a $80.00 target price on the stock. Truist Financial increased their price objective on ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a “hold” rating in a report on Monday, April 21st. JPMorgan Chase & Co. started coverage on ANI Pharmaceuticals in a report on Wednesday, March 12th. They set an “overweight” rating and a $85.00 price objective for the company. Wall Street Zen lowered ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, April 24th. Finally, HC Wainwright reiterated a “buy” rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, March 17th.

Insider Buying and Selling

In other ANI Pharmaceuticals news, SVP Ori Gutwerg sold 881 shares of the stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $60.07, for a total transaction of $52,921.67. Following the sale, the senior vice president now directly owns 89,897 shares of the company’s stock, valued at approximately $5,400,112.79. This trade represents a 0.97% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Christopher Mutz sold 4,000 shares of the stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $60.45, for a total value of $241,800.00. Following the sale, the insider now directly owns 107,317 shares in the company, valued at $6,487,312.65. This represents a 3.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 5,681 shares of company stock worth $346,854 in the last 90 days. Insiders own 11.10% of the company’s stock.

Institutional Investors Weigh In On ANI Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Millennium Management LLC grew its position in shares of ANI Pharmaceuticals by 89.3% during the 4th quarter. Millennium Management LLC now owns 1,002,849 shares of the specialty pharmaceutical company’s stock valued at $55,437,000 after acquiring an additional 473,097 shares during the period. Global Alpha Capital Management Ltd. grew its position in shares of ANI Pharmaceuticals by 17.8% during the 1st quarter. Global Alpha Capital Management Ltd. now owns 735,590 shares of the specialty pharmaceutical company’s stock valued at $49,248,000 after acquiring an additional 111,040 shares during the period. Dimensional Fund Advisors LP grew its position in shares of ANI Pharmaceuticals by 4.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 685,730 shares of the specialty pharmaceutical company’s stock valued at $37,906,000 after acquiring an additional 30,420 shares during the period. Deep Track Capital LP grew its position in shares of ANI Pharmaceuticals by 28.6% during the 4th quarter. Deep Track Capital LP now owns 649,042 shares of the specialty pharmaceutical company’s stock valued at $35,879,000 after acquiring an additional 144,214 shares during the period. Finally, William Blair Investment Management LLC grew its position in shares of ANI Pharmaceuticals by 2.2% during the 4th quarter. William Blair Investment Management LLC now owns 485,268 shares of the specialty pharmaceutical company’s stock valued at $26,826,000 after acquiring an additional 10,440 shares during the period. 76.05% of the stock is owned by institutional investors and hedge funds.

ANI Pharmaceuticals Stock Down 0.2%

Shares of NASDAQ ANIP opened at $65.81 on Friday. The company has a current ratio of 2.66, a quick ratio of 1.98 and a debt-to-equity ratio of 1.46. The stock has a market capitalization of $1.43 billion, a PE ratio of -51.82 and a beta of 0.55. The stock’s fifty day simple moving average is $64.38 and its two-hundred day simple moving average is $61.55. ANI Pharmaceuticals has a 12-month low of $52.50 and a 12-month high of $77.00.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.37 by $0.33. The business had revenue of $197.12 million for the quarter, compared to analysts’ expectations of $179.75 million. ANI Pharmaceuticals had a positive return on equity of 21.35% and a negative net margin of 3.12%. The business’s revenue for the quarter was up 43.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.82 EPS. As a group, analysts expect that ANI Pharmaceuticals will post 3.86 EPS for the current fiscal year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.